Cover Image
市場調查報告書

亨丁頓舞蹈症治療的全球市場

Huntington's Disease Therapeutics

出版商 Global Industry Analysts, Inc. 商品編碼 121147
出版日期 內容資訊 英文 122 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
亨丁頓舞蹈症治療的全球市場 Huntington's Disease Therapeutics
出版日期: 2015年03月01日 內容資訊: 英文 122 Pages
簡介

本報告提供全球亨丁頓舞蹈症治療藥市場相關調查,提供您產業概要與趨勢,2014∼2020年的預測,並彙整各地區趨勢,企業簡介等資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 序論
    • 目前亨丁頓舞蹈症的治療
    • 亨丁頓舞蹈症:概要
    • 市場機會
    • 主要地區/國家的亨丁頓舞蹈症罹患率
    • 目前亨丁頓舞蹈症管理策略的有效性
    • 治療方法和藥物
    • 替代治療
    • 未核準的處方藥
  • 市場趨勢
  • 亨丁頓舞蹈症開發平台分析
  • 亨丁頓舞蹈症領域的劃時代研究
  • 亨丁頓舞蹈症概要
    • 簡介
    • 歷史背景
    • 預後
    • 分期
    • 症狀和前兆
    • 亨丁頓舞蹈症的遺傳學
    • 亨丁頓舞蹈症的診斷
    • 亨丁頓舞蹈症的診斷檢驗
    • 治療方法
  • 近幾年的產業活動
  • 主要企業
    • Alnylam Pharmaceuticals, Inc.
    • Auspex Pharmaceuticals, Inc.
    • Intellect Neurosciences Incorporation
    • Lundbeck A/S
    • Prana Biotechnology Limited
    • Raptor Pharmaceuticals Corp.
    • Sangamo Biosciences, Inc.
    • Teva Pharmaceutical Industries Ltd
    • Trophos SA
    • Valeant Pharmaceuticals International, Inc.
    • Vertex Pharmaceuticals Incorporated
  • 全球市場預測

第3章 市場

  • 美國
  • 歐洲
    • 法國
    • 德國
    • 英國
    • 西班牙
  • 其他各國

第4章 競爭環境

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6280

This report analyzes the worldwide markets for Huntington's Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as -

Alnylam Pharmaceuticals, Inc.
Auspex Pharmaceuticals, Inc.
Intellect Neurosciences Incorporation
Lundbeck A/S
Prana Biotechnology Limited

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • A Prelude
  • Current HD Treatment
  • Huntington's Disease - Quick Facts
  • Market Opportunity
  • Huntington's Disease Prevalence in Major Region/Countries
  • Competition in the Global HD Therapeutics Market is Non-existent
  • Effectiveness of Current HD Management Strategies
  • HD Treatment and Drugs: Brief Description of Disorder, Medication and Side-Effects
  • Alternative Treatment Approaches for Huntington's Disease
  • Alternate Approaches and Therapies
  • Off-Label Prescriptions
  • Select Off-Label Drugs Prescribed for Huntington's Disease: Drug Name & Manufacturer; Treatment Class; and Primary Indication
  • mHtt Aggregates in HD-Molecular Pathogenesis

2. HD THERAPEUTICS MARKET TRENDS

  • Therapeutics Focus on Reduction of mHtt Expression
  • Companies Boost R&D Spending for HD Therapeutics
  • Improved Diagnostics Fueling Interest of Companies in HD Research
  • Support Organizations Play an Instrumental Role in HD Research and Awareness
  • Public-Private Partnerships: A Shot in the Arm
  • HD Research Attracts 'Big Pharma' Investment
  • Pre-Symptomatic Patients to Expand Market Base
  • HDSA Pushes for Improvement in Medicare Funding for Huntington's Disease
  • GINA for Reducing Discrimination Faced by People with HD

3. HUNTINGTON'S DISEASE PIPELINE ANALYSIS

  • A Quick Primer
  • Drug Development Pipeline Reveals a Promising Picture
  • Select Drugs and Supplements in HD Research Pipeline (2014): Drug Name, Manufacturer, Mode of Action and Current Status
  • An Overview of Select Drugs in Late-Stage Clinical Trials
  • SD-809
  • RP103 (Procysbi)
  • PBT2
  • Huntexil(tm) (Pridopidine)
  • Other Novel Approaches for HD Treatment
  • Cellular Delivery of Neurotropic Agents
  • Cogane
  • COPREXA
  • Histone Deacetylases (HDAC)
  • Melatonin, Coenzyme Q-Free Radical Scavengers
  • RNAi - RNA Interference

4. RESEARCH BREAKTHROUGHS IN HD ARENA

  • Triglyceride Oil 'Triheptanoin' Shows Promise for HD Therapeutics
  • Reducing mTORC1 Activation through Drug/Diet May be Helpful
  • Better Understanding of Early Neuronal Changes Lead to Targeted Drug Development
  • Lund University Researchers Successfully Map Functionality of Hypothalamus in HD
  • MIB, University of Lisbon and University of Leicester Demonstrate Latest Findings on KMO Enzyme
  • Latest TRACK-HD Findings Demonstrate Early Identification of Huntington's Disease Progression in Patients
  • Researchers at BUSM, MGH, Columbia University and McLean BTRC Demonstrate Impact of Huntington's Disease on Human Brain
  • Researchers Demonstrate Significance of TFEB and PGC-1alpha Proteins in Prevention of HD
  • Florey Neuroscience Institutes Demonstrates Importance of Cognitive Stimulation in HD Patients
  • University of Wisconsin-Madison Waisman Center Demonstrates Stem Cell Therapy Potential for Treating HD
  • NUI Galway Announces Discovery of Experimental Drugs with Potential for Slowing Progress of HD
  • Lawrence Berkeley National Laboratory Designs Compound for Suppressing HD Symptoms
  • Development of HD Affected Human Brain Cells for Investigative Purposes
  • Device Implant in Brain Exhibits Therapeutic Potential for HD
  • Sangamo Biosciences on Path to Discover a Therapy for HD
  • Scientists at University of Rochester Medical Center Demonstrate Use of Coenzyme Q10 for Reduction of Oxidative Damage in HD Patients

5. AN OVERVIEW OF HUNTINGTON'S DISEASE

  • Introduction
  • Historical Background
  • Prognosis
  • Stages of HD
  • Symptoms and Signs
  • Physical Symptoms
  • Emotional Symptoms
  • Mental Symptoms
  • Genetics of Huntington's Disease
  • Inheritance
  • Mechanism
  • Functions of HTT
  • Effects of mHTT on Cells
  • Macroscopic Effects of mHTT
  • Diagnosis of HD
  • Clinical Diagnosis
  • Embryonic Diagnosis
  • Differential Diagnosis
  • Diagnostic Tests for Huntington's Disease
  • Confirmatory Diagnostic Test
  • Pre-symptomatic Diagnostic Test
  • Prenatal Diagnostic Test
  • Treatment Options
  • Nutrition and Eating
  • Social Activity
  • Speech Therapy
  • Physical Therapy
  • Occupational Therapy
  • Medication
  • Molecular Chaperones

6. RECENT INDUSTRY ACTIVITY

  • Auspex Reports Favorable Study Results of SD-809
  • Sangamo and Collaborators to Present ZFP Therapeutics(r) Data
  • Sangamo Presents Positive Preclinical Data of ZFP Therapeutic(r)
  • Sangamo BioSciences Acquires Ceregene
  • Prana Completes Reach2HD Trial
  • Teva Pharmaceuticals Forms Global R&D Collaboration for HD
  • KineMed, Isis and CHDI Foundation Collaborate for HD Therapeutics
  • CHDI Foundation Continues Collaboration with Medtronic
  • Roche Enters into Alliance with Isis Pharmaceuticals
  • Omeros Receives IND Approval for OMS824 for Huntington's Disease
  • Teva Pharmaceutical Industries Signs Asset Transfer Agreement with NeuroSearch
  • uniQure and Benitec Biopharma Ink Cross-Licensing Agreement
  • Evotec and CHDI Foundation Extend Collaboration
  • Raptor Acquires Exclusive Rights to Cysteamine and Associated Compounds
  • GNS Healthcare Enters into Collaboration with CHDI Foundation
  • Lundbeck Collaborates with CHDI Foundation for HD Research
  • Horizon Discovery Collaborates with Institute of Neurology, London
  • Thomson Reuters and CHDI Foundation Enter into MetaMiner Partnership

7. FOCUS ON SELECT PLAYERS

  • Alnylam Pharmaceuticals, Inc. (US)
  • Auspex Pharmaceuticals, Inc. (US)
  • Intellect Neurosciences Incorporation (US)
  • Lundbeck A/S (Denmark)
  • Prana Biotechnology Limited (Australia)
  • Raptor Pharmaceuticals Corp. (US)
  • Sangamo Biosciences, Inc. (US)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Trophos SA (France)
  • Valeant Pharmaceuticals International, Inc. (Canada)
  • Vertex Pharmaceuticals Incorporated (US)

8. GLOBAL MARKET PERSPECTIVE

    • Table 1: World Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 2: World Historic Review for Huntington's Disease Therapeutics by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)
    • Table 3: World 12-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, and Rest of World Markets for the Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • HDSA Brings about Improved Medicare Funding for Huntington's Disease
    • GINA for Reducing Discrimination Faced by People with HD
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 4: The US Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 5: The US Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2. EUROPE

  • Market Analysis
    • Table 6: European Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - France, Germany, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 7: European Historic Review for Huntington's Disease Therapeutics by Geographic Region - France, Germany, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)
    • Table 8: European 12-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, UK, Spain and Rest of Europe Markets for the Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

2a. FRANCE

  • A. Market Analysis
    • Trophos Sa - A Key Player
  • B. Market Analytics
    • Table 9: French Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 10: French Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2b. GERMANY

  • A. Market Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 11: German Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 12: German Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2c. THE UNITED KINGDOM

  • A. Market Analysis
    • Outlook
    • Table 13: Juvenile HD Incidence Estimates in the UK(includes corresponding Graph/Chart)
    • Table 14: Juvenile HD Prevalence Estimates in the UK (2006-2010) (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 15: The UK Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 16: The UK Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2d. SPAIN

  • A. Market Analysis
    • KEY PLAYER - SOM BIOTECH
  • B. Market Analytics
    • Table 17: Spanish Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 18: Spanish Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2e. REST OF EUROPE

  • A. Market Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 19: Rest of Europe Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 20: Rest of Europe Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

3. REST OF WORLD

  • A. Market Analysis
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 21: Rest of World Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 22: Rest of World Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

  • Total Companies Profiled: 25 The United States (13) Canada (1) Europe (8) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (3) Asia-Pacific (Excluding Japan) (3)

COMPETITIVE LANDSCAPE

Back to Top